Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background

被引:85
作者
Itti, Emmanuel [1 ,3 ]
Juweid, Malik E. [2 ]
Haioun, Corinne [4 ]
Yeddes, Imene
Hamza-Maaloul, Fatma
El Bez, Intidhar
Evangelista, Eva
Lin, Chieh [5 ,6 ]
Dupuis, Jehan [4 ]
Meignan, Michel [3 ]
机构
[1] Hop Henri Mondor, Assistance Publ Hop Paris, Dept Nucl Med, Nucl Med Serv, F-94010 Creteil, France
[2] Univ Iowa, Div Nucl Med, Iowa City, IA USA
[3] Univ Paris 12, CNRS, EAC 7054, Creteil, France
[4] Hop Henri Mondor, Assistance Publ Hop Paris, Dept Clin Hematol, F-94010 Creteil, France
[5] Chang Gung Mem Hosp & Univ, Dept Nucl Med, Tao Yuan, Taiwan
[6] Chang Gung Mem Hosp & Univ, Mol Imaging Ctr, Tao Yuan, Taiwan
关键词
PET; lymphoma; prognosis; response; POSITRON-EMISSION-TOMOGRAPHY; STAGE HODGKINS LYMPHOMA; SUV-BASED ASSESSMENT; RESPONSE ASSESSMENT; INTERNATIONAL WORKSHOP; FDG-PET; INTERIM; CHEMOTHERAPY; CRITERIA; THERAPY;
D O I
10.2967/jnumed.110.080556
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study investigated whether the reference background above which a residual mass is considered positive in the International Harmonization Project criteria should be modified for early F-18-FDG PET evaluation. Methods: In 92 patients with newly diagnosed diffuse large B-cell lymphoma, the maximal standardized uptake value (SUVmax) was measured on post-cycle 2 PET in the most intense residual mass (or, in the case of negative PET findings, in the area of most intense tumor uptake before therapy), in the mediastinal blood pool (MBP) and the liver, as potential reference background tissues. Results: With MBP as a reference (SUVmax, 2.0 +/- 0.6), PET was unable to distinguish early responders from nonresponders. In contrast, with liver as a reference (SUVmax, 2.5 +/- 0.7), 2-y progressionfree survival was significantly different between patients with PET-negative findings (81.8% [95% confidence interval, 71%-93%]) and patients with PET-positive findings (51.8% [95% confidence interval, 35%-69%], P = 0.003). Conclusion: When assessing early response, particularly in risk-adapted therapeutic trials, it seems preferable to refer to a background tissue (liver) with a higher level of uptake than that of current international criteria (MBP) which were designed for end-of-treatment evaluation.
引用
收藏
页码:1857 / 1862
页数:6
相关论文
共 23 条
[1]   Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma [J].
Barrington, Sally F. ;
Qian, Wendi ;
Somer, Edward J. ;
Franceschetto, Antonella ;
Bagni, Bruno ;
Brun, Eva ;
Almquist, Helen ;
Loft, Annika ;
Hojgaard, Liselotte ;
Federico, Massimo ;
Gallamini, Andrea ;
Smith, Paul ;
Johnson, Peter ;
Radford, John ;
O'Doherty, Michael J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (10) :1824-1833
[2]  
Brepoels L, 2007, J NUCL MED, V48, P390
[3]  
CASASNOVAS O, 2 INT WORKSH INT PET
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]  
*CLINICALTRIALS GO, STUD 2 ASS RIT CHEM
[6]  
*CLINICALTRIALS GO, POS EM TOM GUID THER
[7]   Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study [J].
Gallamini, Andrea ;
Hutchings, Martin ;
Rigacci, Luigi ;
Specht, Lena ;
Merli, Francesco ;
Hansen, Mads ;
Patti, Caterina ;
Loft, Annika ;
Di Raimondo, Francesco ;
D'Amore, Francesco ;
Biggi, Alberto ;
Vitolo, Umberto ;
Stelitano, Caterina ;
Sancetta, Rosario ;
Trentin, Livio ;
Luminari, Stefano ;
Iannitto, Emilio ;
Viviani, Simonetta ;
Pierri, Ivana ;
Levis, Alessandro .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3746-3752
[8]   [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:: an early prognostic tool for predicting patient outcome [J].
Haioun, C ;
Itti, E ;
Rahmouni, A ;
Brice, P ;
Rain, JD ;
Belhadj, K ;
Gaulard, P ;
Garderet, L ;
Lepage, E ;
Reyes, F ;
Meignan, M .
BLOOD, 2005, 106 (04) :1376-1381
[9]   Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study [J].
Horning, Sandra J. ;
Juweid, Malik E. ;
Schoeder, Heiko ;
Wiseman, Gregory ;
McMillan, Alex ;
Swinnen, Lode J. ;
Advani, Ranjana ;
Gascoyne, Randy ;
Quon, Andrew .
BLOOD, 2010, 115 (04) :775-777
[10]   Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters [J].
Huettmann, Andreas ;
Mueller, Stefan ;
Bockisch, Andreas ;
Mesters, Rolf ;
Kroschinsky, Frank ;
Prange-Krex, Gabriele ;
Thomssen, Henrike ;
Giagounidis, Aristoteles ;
Duehrsen, Ulrich .
BLOOD, 2009, 114 (22) :1054-1054